StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Stock Down 3.4 %

Shares of NASDAQ APVO opened at $0.17 on Thursday. Aptevo Therapeutics has a 1 year low of $0.14 and a 1 year high of $21.56. The business has a 50-day moving average of $0.37 and a two-hundred day moving average of $1.27.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, beating the consensus estimate of ($1.93) by $0.26. Equities research analysts anticipate that Aptevo Therapeutics will post -4.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent SEC filing. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.